CSBR
Get informed when a big investor buys or sells
+ FollowUndervalued by 207.9% based on the discounted cash flow analysis.
| Market cap | $81.03 Million |
|---|---|
| Enterprise Value | $87.27 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.34 |
| Beta | 0.43 |
| Outstanding Shares | 13,886,797 |
| P/E Ratio | -35.52 |
|---|---|
| PEG | 33.45 |
| Price to Sales | 5.69 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 5.8 |
| Enterprise Value to EBIT | -34.17 |
| Enterprise Value to Net Income | -39 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 3.12 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | 23,200▼ 35.73% |
Holdings and activity of institutional investors.
| Ownership % | 41.28%▼ 0.42% |
|---|---|
| Total Invested | $32.96M▼ 17.06% |
| Investors Holding | 25▼ 2.00% |
No data
Champions Oncology is a data-driven research organization that leverages an oncology research center of excellence to develop transformative technology and accelerate oncology research and development. This technology ranges from computa...